Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Alper H.YUKSEL who wrote (10068)	10/23/1997 6:14:00 PM
From: Hippieslayer	Read Replies (3) \| Respond to of 32384

Re: Analyst Coverage I am still baffled as to how the LGND/LLY deal was received by Wall St. The analysts that cover the stock, based on what was posted on this thread, all seemed to think is was better than what they originally expected-one terming it a "blockbuster". I would have thought, based on the magnitude of the deal, that other brokerage firms who are not covering the stock would do so. I wasn't expecting the whole street to go gaga over LGND, but the stock is no better off now than it was before the deal. I'd even say the stock is worse off now (I concede that today's market in response to the huge burp in SE Asian markets didn't help and yes there are early signs of a base forming at 16). I was just hopefull for new recs to bring LGND out from the backstage and onto the catwalk. A lot of my frustration is due to the action of CORR and IDPH and, until recently, GERN. Just call it "STOCK ENVY".